

## **Oncology Biomarkers: Global Markets**

Market Research Report | 2023-06-15 | 186 pages | BCC Research

### **AVAILABLE LICENSES:**

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

### **Report description:**

Description

Report Scope:

This study provides a comprehensive analysis of oncology biomarkers on a global basis. It aims to offer a range of information, from detailed market analyses within cancer types to overall industry trends, to quantify and qualify the market for products and services in the oncology biomarkers segment. Current and projected market forecasts during the forecast period (2023 to 2028) are discussed. Figures for 2023 are estimated, except where actual results have been reported.

This report includes forecasts by biomarker type, cancer type, application, and region from 2023 through 2028. The report also includes an analysis of leading and emerging competitors in the current worldwide oncology biomarkers market. The competitive environment is examined with a particular focus on how new products and technologies influence the current standard of care.

Report Includes:

- 21 data tables and 60 additional tables
- An in-depth analysis of the global oncology biomarkers market
- Analyses of global market trends, with data from 2020, 2021, 2022, and projections of compound annual growth rates (CAGRs) through 2028
- Characterization and quantification of biomarkers market by type, profiling technology, application, cancer type, and region
- Discussion on market drivers, challenges and key market strategies and trends
- Information on emerging products and technologies, new analytical platforms, novel immunoassays, and bioinformatics tools and discussion on the use of biomarkers in cancer drug development
- Profiles of the competitive landscape with an overview of competitor growth strategies and opportunities

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scott-international.com](mailto:support@scott-international.com)

[www.scott-international.com](http://www.scott-international.com)

Company profiles of major players within the industry, including Abbott, F. Hoffmann-La Roche Ltd., Merck KGaA, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.

## Executive Summary

### Summary:

By definition, biomarkers are any measurable substance that changes in quantity or appears or disappears with a change in a body's state. Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers.

Biomarkers allow early disease identification, improved diagnoses, and safer and more efficacious treatments, leading to better patient outcomes and efficient and effective public expenditure on health. Thus, biomarkers are accelerating throughout the cancer care spectrum (screening, diagnosis, prognosis, therapy selection, prediction, response monitoring, and recurrence monitoring) to improve patient care and treatment outcomes. Also, given the growing burden of cancer on the healthcare ecosystem, there is significant growth in research funding and initiatives to find new clinically relevant biomarkers to understand cancer biology. The discovery of cancer biomarkers is expanding at an unprecedented rate, as previous investments in genomic and proteomic sciences are enabling an improved understanding of disease mechanisms and individual patient responses to therapy. Several cancer biomarkers identified in the past decade are under investigation for their potential applications. Once these biomarkers are validated and subsequently enter clinical and research applications, the oncology biomarkers market is expected to grow significantly.

The global oncology biomarkers market was valued at \$REDACTED billion in 2022. That is projected to grow to \$REDACTED billion in 2028. There is a clear shift toward treating cancers based on their tumor genetics rather than their site of origin in the body. The increasing role of biomarkers in clinical diagnostics, precision medicine, and clinical trial management supports growth in this market. Driven by the rising prevalence of cancer, increasing demand in the therapeutic selection and prognosis, precision medicine, and clinical diagnostics, and a growing number of public/private collaborations and government support, the global market for oncology biomarkers is projected to rise at a CAGR of REDACTED% through 2028.

Genomic biomarkers are more expensive to assay than protein biomarkers. However, with patients gaining access, oncologists and other providers are becoming more accustomed to incorporating genomic diagnostics into routine care, and the genomic biomarkers market is expected to witness rapid growth in coming years. This market is expected to reach \$REDACTED billion in 2028, growing at a CAGR of REDACTED% through the forecast period.

### **Table of Contents:**

Table of Contents

Chapter 1 Introduction

Study Goals and Objectives

Reasons for Doing This Study

Scope of Report

Methodology and Information Sources

Geographic Breakdown

Analyst's Credentials

BCC Custom Research

Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Outlook

Chapter 4 Market and Technology Background

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Overview of Biomarkers  
Classification of Biomarkers  
Types of Biomarkers  
Biomarker Discovery, Verification and Validation  
Overview of Cancer  
Cancer/Oncology Biomarkers  
Oncology Biomarkers Testing Methods  
Oncology Biomarkers Testing Types  
Biomarker Test Development and Marketing  
Chapter 5 Market Dynamics  
Drivers  
Rising Incidence of Cancer  
Increasing Use of Biomarkers in Drug Discovery and Development  
Developments in Analytical Technologies and Assay Methods  
Increased Availability and Ease of Biomarker Testing  
Support from Regulatory Agencies  
Barriers  
Inadequate Patient Access to and Insurance Coverage of Biomarker Testing  
Technical Errors and Delayed Test Results  
Low Provider and Patient Awareness  
Suboptimal Tissue Procurement and Triaging  
Shortages of Laboratories and Personnel  
Chapter 6 Market Breakdown by Biomarker Type  
Protein Biomarkers  
Protein Biomarkers Profiling Technologies  
Genomic Biomarker  
Genomic Biomarkers Profiling Technologies  
Other Biomarkers  
Metabolomic Biomarkers  
Cellular Biomarkers  
Global Market for Oncology Biomarkers, by Biomarker Type  
Protein Biomarkers  
Genomic Biomarkers  
Other Biomarkers  
Chapter 7 Market Breakdown by Application  
Life Science Research  
Risk Assessment and Screening  
Diagnostics  
Prognostics  
Therapeutic Selection and Clinical Trials  
Monitoring  
Response Monitoring  
Recurrence/Minimal Residual Disease (MRD) Monitoring  
Global Market for Oncology Biomarkers by Application  
Life Science Research  
Risk Assessment and Screening  
Diagnostics

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Prognostics  
Therapeutic Selection and Clinical Trials  
Monitoring  
Chapter 8 Market Breakdown by Cancer Type  
Market Overview  
Breast Cancer  
Lung Cancer  
Colorectal Cancer (CRC)  
Prostate Cancer  
Bladder Cancer  
Melanoma  
Leukemia  
Others  
Ovarian Cancer  
Liver Cancer  
Thyroid Cancer  
Cervical Cancer  
Kidney Cancer  
Endometrial Cancer  
Global Market for Oncology Biomarkers by Cancer Type  
Breast Cancer  
Lung Cancer  
Colorectal Cancer  
Prostate Cancer  
Bladder Cancer  
Melanoma  
Leukemia  
Other Cancers  
Chapter 9 Market Breakdown by Region  
Global Market for Oncology Biomarkers by Region  
North America  
Market Revenue by Application  
Market Revenue by Country  
Europe  
Market Revenue by Application  
Market Revenue by Country  
Asia-Pacific  
Market Revenue by Application  
Market Revenue by Country  
Rest of World  
Market Revenue by Application  
Chapter 10 Impact of COVID-19  
Overview  
Implications on Cancer Diagnosis  
Implications on Cancer Treatment  
Impact on Oncology Biomarkers Market  
Chapter 11 Emerging Trends and Technologies in the Market

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Emerging Technologies and Trends in the Market

Liquid Biopsy

Circulating Free Nucleic Acids

Circulating Cell-Free DNA (CfDNA)

"Organ Agnostic" Biomarker Testing

PD-L1

Homologous Recombination Deficiency (HRD)

Blood Test for Early-Stage Cancer Detection

Chapter 12 Competitive Landscape

Overview

Mergers and Acquisitions

SWOT Analysis for Global Oncology Biomarker Market

Porter's Five Forces Analysis of Global Oncology Biomarker Market

Chapter 13 Company Profiles

AGENDIA INC.

ABBOTT

AGILENT TECHNOLOGIES INC.

BIOCARTIS NV

BIOMERIEUX S.A.

BIO-RAD LABORATORIES INC.

BECTON, DICKINSON & CO.

EXACT SCIENCES CORP.

F. HOFFMANN-LA ROCHE AG

GUARDANT HEALTH INC.

HOLOGIC INC.

ILLUMINA INC.

LEICA BIOSYSTEMS

MERCK KGAA

MYRIAD GENETICS INC.

QIAGEN N.V.

SIEMENS HEALTHINEERS AG

THERMO FISHER SCIENTIFIC INC.

VERACYTE INC.

Chapter 14 Appendix: Acronyms

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Oncology Biomarkers: Global Markets**

Market Research Report | 2023-06-15 | 186 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-02"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)